menu
    • menu

    Company profile for Edge Therapeutics

    NEW Drugs in Dev: 1
    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-03-23

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Edge Therapeutics®, Inc. is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological and other conditions.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Edge TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    300 Connell Drive, Suite 4000 Berkeley Heights, NJ 07922
    Telephone
    Telephone
    800-208-EDGE
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://www.edgetherapeutics.com
    Linkedin
    Linkedin
    https://www.linkedin.com/company/edge-therapeutics-inc-/?originalSubdomain=in
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    CGT Asia

    Not Confirmed

    envelop Contact Supplier

    CGT Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Novotech Unveils 2024 Global Gastric Cancer Trials and Cutting-Edge Therapies
    Novotech Unveils 2024 Global Gastric Cancer Trials and Cutting-Edge Therapies

    04 Sep 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240903559744/en

    BUSINESSWIRE
    04 Sep 2024
    Share Share
    Edge Pharma Completes Supplier Agreement with ANI Pharmaceuticals, Inc
    Edge Pharma Completes Supplier Agreement with ANI Pharmaceuticals, Inc

    24 Jun 2020

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/edge-pharma-completes-supplier-agreement-with-ani-pharmaceuticals-inc-301083167.html

    PRNEWSWIRE
    24 Jun 2020
    Share Share
    Analyst Opinion On How To Bet On TechnipFMC plc (FTI), Edge
    Analyst Opinion On How To Bet On TechnipFMC plc (FTI), Edge

    09 Jul 2018

    // POSTANALYST

    https://postanalyst.com/2018/07/09/analyst-opinion-on-how-to-bet-on-technipfmc-plc-fti-edge-therapeutics-inc-edge/

    POSTANALYST
    09 Jul 2018
    Share Share
    Robbins Arroyo Edge Therapeutics Misled Shareholders According to Class Action
    Robbins Arroyo Edge Therapeutics Misled Shareholders According to Class Action

    05 Jul 2018

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20180705005640/en/Robbins-Arroyo-LLP-Edge-Therapeutics-EDGE-Misled

    BUSINESSWIRE
    05 Jul 2018
    Share Share
    Edge Announces Updated Results from Phase 3 NEWTON 2 Study of EG-1962
    Edge Announces Updated Results from Phase 3 NEWTON 2 Study of EG-1962

    27 Jun 2018

    // PRESS RELEASE

    http://investors.edgetherapeutics.com/phoenix.zhtml?c=253911&p=irol-newsArticle&ID=2356273

    PRESS RELEASE
    27 Jun 2018
    Share Share
    Edge Provides Update following Interim Analysis of Ph3 NEWTON 2 Study EG-1962
    Edge Provides Update following Interim Analysis of Ph3 NEWTON 2 Study EG-1962

    28 Mar 2018

    // PRESS RELEASE

    http://investors.edgetherapeutics.com/phoenix.zhtml?c=253911&p=irol-newsArticle&ID=2340075

    PRESS RELEASE
    28 Mar 2018
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search